Product logins

Find logins to all Clarivate products below.


Biosimilars | Target Product Profile Simulator | Oncology | 2021

Related Market Assessment Reports

Report
Biosimilars – Forecast – Respiratory
In 2024, sales of branded biologics for respiratory indications totaled $7 billion in the major pharmaceutical markets under study (United States, EU5, and Japan). Throughout the 2024-2034 forecast…
Report
Biosimilars – Forecast – Endocrinology
In 2024, sales of branded biologics for endocrinology indications (insulins and antiresorptive analogues) exceeded $22 billion in the major pharmaceutical markets under study (United States, EU5,…
Report
Biosimilars – Forecast – Immunology
In 2024, sales of branded biologics in immunology exceeded $65 billion in the major pharmaceutical markets under study (United States, EU5, and Japan). Sales of biosimilars in the major market in…
Report
Biosimilars – Forecast – Forecast Methodology and General Market Assumptions
In 2024, sales of branded biologics for oncology (except G-CSFs), immunology, endocrinology, ophthalmology, neurology, osteoporosis, and respiratory indications exceeded $160 billion in the major…
Report
Biosimilars – Forecast – Neurology
In 2024, sales of branded MAb biologics in neurology exceeded $12 billion in the major pharmaceutical markets (United States, EU5, and Japan). Throughout our 2024-2034 forecast period, the…